Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model

Yu-Wei Lin, Qi Tony Zhou, Mei-Ling Han, Ke Chen, Nikolas J. Onufrak, Jiping Wang, John D. Turnidge, Benjamin P. Howden, Alan Forrest, Hak-Kim Chan, Jian Li
Yu-Wei Lin
aAdvanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qi Tony Zhou
bDepartment of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mei-Ling Han
cDrug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ke Chen
cDrug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolas J. Onufrak
dDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nikolas J. Onufrak
Jiping Wang
cDrug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Turnidge
eAustralian Commission on Safety and Quality in Health Care, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin P. Howden
fMicrobiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, The University of Melbourne at the Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia
gDepartment of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Forrest
dDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hak-Kim Chan
aAdvanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Li
hMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01790-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The pharmacokinetics/pharmacodynamics (PK/PD) of aerosolized colistin was investigated against Acinetobacter baumannii and Klebsiella pneumoniae over 24 h in a neutropenic mouse lung infection model. Dose fractionation studies were performed over 2.64 to 23.8 mg/kg/day, and the data were fitted to a sigmoid inhibitory model. The area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC) in the epithelial lining fluid was the most predictive PK/PD index for aerosolized colistin against both pathogens. Our study provides important pharmacological information for optimizing aerosolized colistin.

TEXT

Colistin is a polypeptide antibiotic that has been increasingly used as a last-line therapy for pulmonary infections caused by multidrug-resistant (MDR) Gram-negative bacteria (1–6). Inhalation of colistin has been commonly used in the treatment of pulmonary infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (3, 4). However, the pharmacokinetics/pharmacodynamics (PK/PD) of aerosolized colistin has not been examined against Acinetobacter baumannii or Klebsiella pneumoniae (7, 8). Our present study is the first to investigate the PK/PD of aerosolized colistin against both pathogens.

All animal experiments were approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee and conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Female Swiss mice (8 to 10 weeks of age) were obtained from Monash Animal Research Platform (Clayton, Victoria, Australia) or Australian Resources Centre (Perth, Western Australia, Australia). A neutropenic mouse lung infection model was employed as described previously (7, 8) with A. baumannii (ATCC 19606, 248-01-C.248, and N-16870.213; MICs, 1, 1, and 0.5 mg/liter, respectively) and K. pneumoniae (ATCC BAA 2146, 17, and KP1; MICs, 0.5, 1, and 0.25 mg/liter, respectively). For pulmonary administration, mice were briefly anesthetized and placed on a Perspex support in a vertical upright position. A Penn-Century MicroSprayer was used to administer the bacterial suspension (25 μl of approximately 106 to 107 bacterial cells in early logarithmic phase) and colistin solution (2.64, 5.28, and 7.92 mg/base/kg in 25 μl, lot no. 08M1526V, ≥15,000 U/mg; Sigma-Aldrich, St. Louis, MO, USA) to the mouse lungs (9). Although colistin in the form of an inactive prodrug, colistin methanesulfonate (CMS), is used in the clinic, colistin (sulfate) was employed in the present study because the efficacy of nebulized CMS depends on the exposure of formed colistin. Viable cell counts were obtained using a ProtoCOL automated colony counter (Synbiosis ProtoCOL colony counter; Don Whitley Scientific Ltd.), and the limit of counting was 164 CFU/lung (equivalent to one colony per plate).

In vivo time-kill kinetics were measured after a single pulmonary dose of colistin (2.64 and 5.28 mg base/kg, 25 μl) at 2 h after infection; control mice were treated with the same volume of saline. At 0, 1, 3, 6, 16, and 24 h after the treatment, mice were humanely killed, and the lungs were aseptically harvested (n = 3 or more per time point). The time course of bacterial loads in the lungs following a single dose of aerosolized colistin is shown in Fig. 1. Minor differences in bacterial loads were observed between the control and the treated groups (2.64 and 5.28 mg base/kg) for A. baumannii and K. pneumoniae (Fig. 1). Even though regrowth was observed at 24 h across all strains (except A. baumannii ATCCC 19606), bacterial killing by colistin was observed against A. baumannii 248-01-C.248 and A. baumannii N-16870.213 within 6 h of the pulmonary administration, while within 1 h against all three strains of K. pneumoniae. For A. baumannii ATCC 19606, both killing and regrowth were not evident over 24 h. One potential reason for the lack of bacterial killing against A. baumannii ATCC 19606 was probably due to the polymyxin inoculum effect; a much higher inoculum (∼108 CFU/lung) was used for A. baumannii ATCC 19606 as opposed to that for other strains (∼107 CFU/lung). This higher bacterial inoculum of A. baumannii ATCC 19606 was needed to establish a reliable lung infection over 24 h. Interstrain variability was observed for bacterial killing and regrowth following treatment with aerosolized colistin (Fig. 1). Although the colistin MICs were different among the isolates, they were not able to fully predict the efficacy of aerosolized colistin against each isolate. For example, the killing effect against K. pneumoniae KP1 (MIC, 0.25 mg/liter) was similar to or even worse than that against other strains with higher MICs (0.5 to 1 mg/liter) (Fig. 1). Surprisingly, doubling the dose only marginally improved the killing efficacy, and the regrowth was evident (Fig. 1). A possible explanation is that some bacterial cells not directly exposed to aerosolized colistin in the lungs were able to proliferate (4, 10). This was evidenced in a piglet study, wherein after inhalation, the drug penetration decreased with increasing inflammation (10). Even though high colistin exposure is achieved in the epithelial lining fluid (ELF) after inhalation (8), the current single-dose PD profiles show that it is still not possible to completely eradicate bacteria in the lungs (Fig. 1). Regrowth was evident with all isolates (except A. baumannii ATCC 19606), even though the ELF concentration remained well above the MIC over the 12-h sampling period (8). This regrowth could also be due to adaptive resistance, whereby colistin resistance was developed by A. baumannii through the loss or modification of lipopolysaccharides (LPS) (11, 12), while in K. pneumoniae, through the modification of LPS or the upregulation of capsule polysaccharides (13, 14). The exact mechanisms for the regrowth after aerosolized colistin remain unknown, and further studies are warranted.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

In vivo time-kill kinetics of aerosolized colistin (2.64 and 5.28 mg base/kg) in a neutropenic mouse lung infection model. (A) A. baumannii ATCC 19606, (B) A. baumannii 248-01-C.248, (C) A. baumannii N16870.213, (D) K. pneumoniae ATCC BAA 2146, (E) K. pneumoniae 17, and (F) K. pneumoniae KP1. The limit of detection is 164 CFU/lung. Data points represent means ± standard deviations (n = 3 or more per time point).

To optimize the PK/PD of aerosolized colistin, a dose fractionation study was conducted to delineate the PK/PD indices. As mice were not able to tolerate >7.92 mg base/kg aerosolized colistin in a single dose or a cumulative dose of >23.8 mg base/kg, dose fractionation studies were performed over 2.64 to 23.8 mg/kg/day, including once-daily 2.64, 5.28, and 7.92 mg base/kg, twice-daily (12 hourly) 5.28 and 7.92 mg base/kg, and thrice-daily (8 hourly) 2.64, 5.28, and 7.92 mg base/kg doses (n = 3 or more for each group). Each pulmonary administration was performed under light anesthesia. At 0 or 24 h after the initiation of the first inhaled colistin dose, mice were humanely killed and the lungs were harvested for viable counting. Subsequently, the data were fitted to a sigmoid inhibitory model (7). For A. baumannii and K. pneumoniae, the ratios of the area under the colistin concentration-time curve over 24 h in the steady state to the MIC in ELF (AUCELF/MIC) and in plasma (fAUCPlasma/MIC) were the most predictive PK/PD indices for the efficacy of aerosolized colistin in neutropenic mice (Table 1 and Fig. 2 and 3; see also Fig. S1 to S4 in the supplemental material); a much better correlation was observed than with the maximum concentration of colistin divided by the MIC (Cmax/MIC) and the cumulative percentage of time that the colistin concentration exceeds the MIC at steady-state PK (%T>MIC) in both ELF and plasma (Table 1 and Fig. 2 and 3). Unlike the previous observations with P. aeruginosa (8), a higher degree of interstrain variability in AUCELF/MIC and fAUCplasma/MIC was observed with K. pneumoniae (Table 2). Even with the highest tolerable aerosolized colistin dose, it was not possible to achieve >2-log10 kill at 24 h against two isolates of K. pneumoniae (Table 2). A lower efficacy (i.e., inability to achieve a 2-log10 kill) for aerosolized colistin against K. pneumoniae than against A. baumannii and P. aeruginosa might be related to the capsule which has been reported as a mechanism of polymyxin resistance in K. pneumoniae but not the other two species (14–16). A lower therapeutic response against K. pneumoniae was also noted for systemic polymyxin B in a neutropenic mouse thigh infection model (17). The exact mechanism for the differences in the in vivo efficacy of colistin against different bacterial species requires further investigations.

View this table:
  • View inline
  • View popup
TABLE 1

PK/PD model parameters for AUC/MIC of aerosolized colistin in the ELF and plasma against A. baumannii and K. pneumoniaee

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Relationship between the bacterial load in the lungs (log10 CFU/lung) and the PK/PD indices for ELF, AUCELF/MIC (A), Cmax,ELF/MIC (B), and %T>MIC, ELF (C), and for plasma, fAUCplasma/MIC (D), fCmax,plasma/MIC (E), and (F) %fT>MIC, Plasma against A. baumannii 248-01-C.248 following pulmonary administration of colistin. The dashed lines represent the average bacterial burden in the lungs at the start of aerosolized colistin treatment. Data points on the y axis are for the untreated mice (saline control) at 24 h after the commencement of the inhaled therapy.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Relationship between the bacterial load in the lungs (log10 CFU/lung) and the PK/PD indices for ELF, AUCELF/MIC (A), Cmax,ELF/MIC (B), and %T>MIC, ELF (C), and for plasma, fAUCplasma/MIC (D), fCmax,plasma/MIC (E), and %fT>MIC, Plasma (F) against K. pneumoniae 17 following pulmonary administration of colistin. The dashed lines represent the average bacterial burden in the lungs at the start of aerosolized colistin treatment. Data points on the y axis are for the untreated mice (saline control) at 24 h after the commencement of the inhaled therapy.

View this table:
  • View inline
  • View popup
TABLE 2

Targets of AUCELF/MIC and fAUCplasma/MIC associated with bacteriostasis and 1- and 2-log10 kills against A. baumannii and K. pneumoniae in neutropenic infected mice after aerosolized colistin

Pulmonary administration of colistin was much more effective than systemic delivery for the treatment of respiratory tract infections caused by Gram-negative pathogens (7, 8). To achieve the antibacterial stasis against A. baumannii 248-01-C.248, the fAUCplasma/MIC required with subcutaneous administration (11.6) (7) is 14-fold higher than that required with pulmonary administration (0.86) (Table 2). This is consistent with the finding from a study by Chiang et al. (18), in which bacterial load, survival rate, wet lung/body weight ratio, and histopathological changes were examined in neutropenic mice with lung infections of A. baumannii, where the pulmonary administration of colistin (75,000 IU/kg thrice daily) was more efficacious than intraperitoneal administration (150,000 IU/kg thrice daily). Likewise, Bowers et al. reported a lack of responsiveness for intraperitoneally administered polymyxin B (10 mg/kg) for treating lung infections caused by A. baumannii in neutropenic mice (19). The superior efficacy of aerosolized colistin as opposed to parenteral administration against lung infections was also reported with K. pneumoniae. In a neutropenic mouse lung infection model, the subcutaneous administration of colistin was not able to achieve bacteriostasis against K. pneumoniae (17). In the present study, mild killing against K. pneumoniae was evident with aerosolized colistin and bacteriostasis was achieved against all three isolates (Table 2). The superior efficacy of aerosolized colistin was not unexpected due to the high exposure in the ELF, and recent PK studies in animals (8, 10, 20–25) and patients (1, 3, 4) have also demonstrated this. Well-designed clinical studies are needed to evaluate nebulized colistin for the management of life-threatening respiratory tract infections caused by MDR Gram-negative pathogens.

Against A. baumannii, K. pneumoniae (except for K. pneumoniae KP1), and P. aeruginosa (8), the AUCELF/MIC targets for bacteriostasis generally fell within the same order of magnitude (Table 2). The high AUCELF/MIC targets (Table 2) were most likely due to the heterogeneous distribution of the colistin aerosol in the respiratory tracts (4) and the binding of colistin to mucin (26) and surfactants in the lungs (27). The calculated PK/PD targets in the ELF can be employed in the Monte Carlo simulation to derive the probability of target attainments to optimize the inhalational dosage regimens of CMS in the clinic (28, 29). However, due to the lack of a robust population PK model in humans after inhalation, it is not possible to perform simulations to compare the AUCELF/MIC targets from the current animal studies with the AUCELF/MIC targets achieved in critically ill patients receiving aerosolized CMS (4, 30). The calculated AUC/MIC targets must be used with a recognition of the potential limitations associated with animal PK/PD studies. First, the plasma protein binding (7, 31) and the abundance of potential transporters (e.g., PEPT2) in lung epithelial cells are species dependent (32–34). Second, the Penn-Century MicroSprayer may have a lower delivery efficiency, as it generates aerosol droplets with an approximately 10-μm diameter, which is larger than those generated by clinically available nebulizers (<10 μm in diameter depending on the types of nebulizer) (22).

To the best of our knowledge, this is the first study to reveal that AUCELF/MIC is the most predictive PK/PD index for the in vivo efficacy of aerosolized colistin against A. baumannii and K. pneumoniae. Our preclinical results provide important pharmacological information for future clinical studies to optimize the dosage regimens of inhaled colistin for treating respiratory tract infections caused by MDR A. baumannii and K. pneumoniae.

ACKNOWLEDGMENTS

This work was supported by the National Health and Medical Research Council ([NHMRC] APP1065046). Q.T.Z., A.F., and J.L. are supported by research grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01 AI111965 [J.L. and A.F.] and R01 AI132681 [Q.T.Z., J.L., and A.F.]).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. Yu-Wei Lin is a recipient of the Australian Postgraduate Award. J.L. is an Australian NHMRC Senior Research Fellow. Q.T.Z. is a recipient of the Ralph W. and Grace M. Showalter Research Trust Award.

FOOTNOTES

    • Received 11 September 2017.
    • Returned for modification 19 October 2017.
    • Accepted 4 December 2017.
    • Accepted manuscript posted online 11 December 2017.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.01790-17.

  • Copyright © 2018 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Athanassa ZE,
    2. Markantonis SL,
    3. Fousteri M-ZF,
    4. Myrianthefs PM,
    5. Boutzouka EG,
    6. Tsakris A,
    7. Baltopoulos GJ
    . 2012. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 38:1779–1786. doi:10.1007/s00134-012-2628-7.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Nakwan N,
    2. Lertpichaluk P,
    3. Chokephaibulkit K,
    4. Villani P,
    5. Regazzi M,
    6. Imberti R
    . 2015. Pulmonary and systemic pharmacokinetics of colistin following a single dose of nebulized colistimethate in mechanically ventilated neonates. Pediatr Infect Dis J 34:961–963. doi:10.1097/INF.0000000000000775.
    OpenUrlCrossRef
  3. 3.↵
    1. Yapa SWS,
    2. Li J,
    3. Patel K,
    4. Wilson JW,
    5. Dooley MJ,
    6. George J,
    7. Clark D,
    8. Poole S,
    9. Williams E,
    10. Porter CJ
    . 2014. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 58:2570–2579. doi:10.1128/AAC.01705-13.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Boisson M,
    2. Jacobs M,
    3. Grégoire N,
    4. Gobin P,
    5. Marchand S,
    6. Couet W,
    7. Mimoz O
    . 2014. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 58:7331–7339. doi:10.1128/AAC.03510-14.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Falagas ME,
    2. Siempos II,
    3. Rafailidis PI,
    4. Korbila IP,
    5. Ioannidou E,
    6. Michalopoulos A
    . 2009. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med 103:707–713. doi:10.1016/j.rmed.2008.11.018.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Falagas ME,
    2. Sideri G,
    3. Korbila IP,
    4. Vouloumanou EK,
    5. Papadatos JH,
    6. Kafetzis DA
    . 2010. Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Pediatr Pulmonol 45:1135–1140. doi:10.1002/ppul.21302.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Cheah S-E,
    2. Wang J,
    3. Turnidge JD,
    4. Li J,
    5. Nation RL
    . 2015. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 70:3291–3297.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Lin Y-W,
    2. Zhou Q,
    3. Cheah S-E,
    4. Zhao J,
    5. Chen K,
    6. Wang J,
    7. Chan H-K,
    8. Li J
    . 2017. Pharmacokinetics/pharmacodynamics of pulmonary delivery of colistin against Pseudomonas aeruginosa in a mouse lung infection model. Antimicrob Agents Chemother 61:e02025-16.
  9. 9.↵
    1. Bivas-Benita M,
    2. Zwier R,
    3. Junginger HE,
    4. Borchard G
    . 2005. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm 61:214–218. doi:10.1016/j.ejpb.2005.04.009.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Lu Q,
    2. Girardi C,
    3. Zhang M,
    4. Bouhemad B,
    5. Louchahi K,
    6. Petitjean O,
    7. Wallet F,
    8. Becquemin M-H,
    9. Le Naour G,
    10. Marquette C-H
    . 2010. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 36:1147–1155. doi:10.1007/s00134-010-1879-4.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Moffatt JH,
    2. Harper M,
    3. Harrison P,
    4. Hale JD,
    5. Vinogradov E,
    6. Seemann T,
    7. Henry R,
    8. Crane B,
    9. St. Michael F,
    10. Cox AD,
    11. Adler B,
    12. Nation RL,
    13. Li J,
    14. Boyce JD
    . 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54:4971–4977. doi:10.1128/AAC.00834-10.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Adams MD,
    2. Nickel GC,
    3. Bajaksouzian S,
    4. Lavender H,
    5. Murthy AR,
    6. Jacobs MR,
    7. Bonomo RA
    . 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 53:3628–3634. doi:10.1128/AAC.00284-09.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Cheng Y-H,
    2. Lin T-L,
    3. Pan Y-J,
    4. Wang Y-P,
    5. Lin Y-T,
    6. Wang J-T
    . 2015. Colistin resistance mechanisms in Klebsiella pneumoniae strains from Taiwan. Antimicrob Agents Chemother 59:2909–2913. doi:10.1128/AAC.04763-14.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Formosa C,
    2. Herold M,
    3. Vidaillac C,
    4. Duval RE,
    5. Dague E
    . 2015. Unravelling of a mechanism of resistance to colistin in Klebsiella pneumoniae using atomic force microscopy. J Antimicrob Chemother 70:2261–2270. doi:10.1093/jac/dkv118.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Campos MA,
    2. Vargas MA,
    3. Regueiro V,
    4. Llompart CM,
    5. Albertí S,
    6. Bengoechea JA
    . 2004. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 72:7107–7114. doi:10.1128/IAI.72.12.7107-7114.2004.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Cheah S-E,
    2. Li J,
    3. Bergen PJ,
    4. Nation RL
    . 2016. Polymyxin pharmacokinetics and pharmacodynamics, p 221–260. In Rotschafer JC, Andes DR, Rodvold KA (ed), Antibiotic pharmacodynamics. Springer, New York, NY. doi:10.1007/978-1-4939-3323-5_10.
    OpenUrlCrossRef
  17. 17.↵
    1. Landersdorfer CB,
    2. Wang J,
    3. Wirth V,
    4. Chen K,
    5. Kaye KS,
    6. Tsuji BT,
    7. Nation RL
    . 14 November 2017. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother doi:10.1093/jac/dkx409.
    OpenUrlCrossRef
  18. 18.↵
    1. Chiang SR,
    2. Chuang YC,
    3. Tang HJ,
    4. Chen CC,
    5. Chen CH,
    6. Lee NY,
    7. Chou CH,
    8. Ko WC
    . 2009. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Crit Care Med 37:2590–2595. doi:10.1097/CCM.0b013e3181a0f8e1.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Bowers DR,
    2. Cao H,
    3. Zhou J,
    4. Ledesma KR,
    5. Sun D,
    6. Lomovskaya O,
    7. Tam VH
    . 2015. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother 59:2720–2725. doi:10.1128/AAC.04110-14.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Yapa SWS,
    2. Li J,
    3. Porter CJ,
    4. Nation RL,
    5. Patel K,
    6. McIntosh MP
    . 2013. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob Agents Chemother 57:5087–5095. doi:10.1128/AAC.01127-13.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Yapa SWS
    . 2013. Target advantage of pulmonary delivery of colistin for treatment of respiratory infections. Monash University, Melbourne, Victoria, Australia.
  22. 22.↵
    1. Marchand S,
    2. Gobin P,
    3. Brillault J,
    4. Baptista S,
    5. Adier C,
    6. Olivier J-C,
    7. Mimoz O,
    8. Couet W
    . 2010. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob Agents Chemother 54:3702–3707. doi:10.1128/AAC.00411-10.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Gontijo AVL,
    2. Grégoire N,
    3. Lamarche I,
    4. Gobin P,
    5. Couet W,
    6. Marchand S
    . 2014. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob Agents Chemother 58:3950–3956. doi:10.1128/AAC.02819-14.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Marchand S,
    2. Bouchene S,
    3. de Monte M,
    4. Guilleminault L,
    5. Montharu J,
    6. Cabrera M,
    7. Grégoire N,
    8. Gobin P,
    9. Diot P,
    10. Couet W
    . 2015. Pharmacokinetics of colistin methansulphonate (CMS) and colistin after CMS nebulisation in baboon monkeys. Pharm Res 32:3403–3414. doi:10.1007/s11095-015-1716-0.
    OpenUrlCrossRef
  25. 25.↵
    1. Landersdorfer CB,
    2. Nguyen T-H,
    3. Lieu LT,
    4. Nguyen G,
    5. Bischof RJ,
    6. Meeusen EN,
    7. Li J,
    8. Nation RL,
    9. McIntosh MP
    . 2017. Substantial targeting advantage achieved by pulmonary administration of colistin methanesulfonate in a large-animal model. Antimicrob Agents Chemother 61:e01934-16. doi:10.1128/AAC.01934-16.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Huang JX,
    2. Blaskovich MA,
    3. Pelingon R,
    4. Ramu S,
    5. Kavanagh A,
    6. Elliott AG,
    7. Butler MS,
    8. Montgomery AB,
    9. Cooper MA
    . 2015. Mucin binding reduces colistin antimicrobial activity. Antimicrob Agents Chemother 59:5925–5931. doi:10.1128/AAC.00808-15.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Schwameis R,
    2. Erdogan-Yildirim Z,
    3. Manafi M,
    4. Zeitlinger M,
    5. Strommer S,
    6. Sauermann R
    . 2013. Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrob Agents Chemother 57:5151–5154. doi:10.1128/AAC.00778-13.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Ikawa K,
    2. Morikawa N,
    3. Ohge H,
    4. Ikeda K,
    5. Sueda T,
    6. Taniwaki M,
    7. Kurisu K
    . 2010. Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients. J Infect Chemother 16:25–32. doi:10.1007/s10156-009-0022-3.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Kuti JL,
    2. Ong C,
    3. Lo M,
    4. Melnick D,
    5. Soto N,
    6. Nicolau DP
    . 2006. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents 28:62–68. doi:10.1016/j.ijantimicag.2006.02.018.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Boisson M,
    2. Grégoire N,
    3. Cormier M,
    4. Gobin P,
    5. Marchand S,
    6. Couet W,
    7. Mimoz O
    . 2017. Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients. J Antimicrob Chemother 72:2607–2612. doi:10.1093/jac/dkx167.
    OpenUrlCrossRef
  31. 31.↵
    1. Linden PK,
    2. Kusne S,
    3. Coley K,
    4. Fontes P,
    5. Kramer DJ,
    6. Paterson D
    . 2003. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37:e154–e160. doi:10.1086/379611.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Bleasby K,
    2. Castle J,
    3. Roberts C,
    4. Cheng C,
    5. Bailey W,
    6. Sina J,
    7. Kulkarni A,
    8. Hafey M,
    9. Evers R,
    10. Johnson J
    . 2006. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:963–988. doi:10.1080/00498250600861751.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Bosquillon C
    . 2010. Drug transporters in the lung—do they play a role in the biopharmaceutics of inhaled drugs? J Pharm Sci 99:2240–2255. doi:10.1002/jps.21995.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Saito H,
    2. Terada T,
    3. Okuda M,
    4. Sasaki S,
    5. Inui K-i
    . 1996. Molecular cloning and tissue distribution of rat peptide transporter PEPT2. Biochim Biophys Acta 1280:173–177. doi:10.1016/0005-2736(96)00024-7.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model
Yu-Wei Lin, Qi Tony Zhou, Mei-Ling Han, Ke Chen, Nikolas J. Onufrak, Jiping Wang, John D. Turnidge, Benjamin P. Howden, Alan Forrest, Hak-Kim Chan, Jian Li
Antimicrobial Agents and Chemotherapy Jan 2018, 62 (2) e01790-17; DOI: 10.1128/AAC.01790-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model
Yu-Wei Lin, Qi Tony Zhou, Mei-Ling Han, Ke Chen, Nikolas J. Onufrak, Jiping Wang, John D. Turnidge, Benjamin P. Howden, Alan Forrest, Hak-Kim Chan, Jian Li
Antimicrobial Agents and Chemotherapy Jan 2018, 62 (2) e01790-17; DOI: 10.1128/AAC.01790-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

polymyxin
respiratory tract infections
pulmonary administration
Acinetobacter baumannii
Klebsiella pneumoniae
Gram-negative bacteria

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596